about
The ubiquitin proteasomal system: a potential target for the management of Alzheimer's diseaseThe role of inflammasome in Alzheimer's diseaseAlzheimer's disease: Unique markers for diagnosis & new treatment modalitiesRapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil.A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's diseaseAntiaggregation Potential of Padina gymnospora against the Toxic Alzheimer's Beta-Amyloid Peptide 25-35 and Cholinesterase Inhibitory Property of Its Bioactive CompoundsMicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer's Disease from Public Data.Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease.Current and future treatments for Alzheimer's diseaseEffects of secondary metabolite extract from Phomopsis occulta on β-amyloid aggregationTrafficking protein particle complex 6A delta (TRAPPC6AΔ) is an extracellular plaque-forming protein in the brain.Novel advances in shotgun lipidomics for biology and medicine.β amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease miceAtrophy of amygdala and abnormal memory-related alpha oscillations over posterior cingulate predict conversion to Alzheimer's diseaseRecent rodent models for Alzheimer's disease: clinical implications and basic research.The role of inflammatory processes in Alzheimer's disease.The role of amyloidogenic protein oligomerization in neurodegenerative disease.Disease progression and neuroscience.Active immunotherapy options for Alzheimer's disease.Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases.Emerging amyloid and tau targeting treatments for Alzheimer's disease.Neuroinflammation in Alzheimer's Disease: Pleiotropic Roles for Cytokines and Neuronal Pentraxins.Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement.Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer's Disease Involves Nrf2/HO-1 PathwaySystematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment
P2860
Q26749321-CD510C00-B4D6-4426-82F3-92554528DFE0Q26996822-E787CD90-2D6F-4853-B4ED-76B5BDD97AF2Q28085139-FDDF7894-9AEE-4227-8318-29B2AF546721Q28315288-7410A267-C8FC-4A21-A6EB-0BB2C38C0821Q28544423-FF016651-605F-47F4-A8BB-7FF0C1261AB5Q28550688-05EEAA4E-FBE0-424E-912F-C95474DA847DQ30940333-E19D6437-53FD-47A4-BB81-561F1A324DC5Q34532864-CCB4DA85-31CD-42E3-B51E-45148BC0805CQ34646921-2B16035B-7899-4681-9214-9B9CA7BB0E6DQ35295380-1D718248-0935-4A01-B313-882D6316326AQ35551814-959BF068-F7B0-4C50-BC4F-52A4618FAA37Q35878177-9BDBE881-18DE-4F31-8508-2CECDB13DD90Q36877633-6268C27B-3241-450B-B69F-1799AE953DC2Q37193075-4ED5DBD9-1847-46E9-B422-F2364CB3F679Q37956513-63C6BD1D-3829-4843-BD2F-E3C8B657EB30Q38005630-15063C3D-47D1-4DB7-BD8C-8EF644004E38Q38093118-80724F68-4149-4E5D-A2DA-82D9C589B7E3Q38099584-F535A57B-2065-4848-A5EB-9967C55F328CQ38183140-24078D19-26D3-4969-B082-FFD17BBFFBC7Q38807256-AE967EDE-A350-4D54-9E91-4D9E28CCE375Q39296311-60F0021B-849C-4739-9D93-452F540E9548Q49808096-DDB76D37-7B0E-4068-84A8-C91ECB88E395Q53446502-7BEB2D1C-C791-4BD9-9FAF-BA1968D10717Q54958322-CF1B355A-488E-4727-9FD3-7C292C2E86EDQ56350501-268DB3EE-C6CE-440E-88BB-19FAF75905B0Q58583583-D6CE5AB4-898D-40E2-A5EF-A889130B6916
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Disease-modifying treatments for Alzheimer's disease.
@ast
Disease-modifying treatments for Alzheimer's disease.
@en
type
label
Disease-modifying treatments for Alzheimer's disease.
@ast
Disease-modifying treatments for Alzheimer's disease.
@en
prefLabel
Disease-modifying treatments for Alzheimer's disease.
@ast
Disease-modifying treatments for Alzheimer's disease.
@en
P2860
P356
P1476
Disease-modifying treatments for Alzheimer's disease.
@en
P2860
P304
P356
10.1177/1756285611404470
P577
2011-07-01T00:00:00Z